MAZE THERAPEUTICS, INC. Increase (Decrease) in Other Operating Liabilities
MAZE THERAPEUTICS, INC. (MAZE) reported Increase (Decrease) in Other Operating Liabilities of $3.48 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-03-25
- MAZE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was $1.96M, a 6.51% increase year-over-year.
- MAZE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was $2.48M.
- MAZE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for the quarter ending 2025-06-30 was $106.00K, a 97.21% decline year-over-year.
- MAZE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for the quarter ending 2025-03-31 was -$1.06M.
- MAZE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for fiscal 2025 was $3.48M, a 8.54% decline from fiscal 2024.
- MAZE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for fiscal 2024 was $3.81M.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.44M derived: sum of 2 quarters · filed 2026-03-25 | $4.54M derived: sum of 3 quarters · filed 2026-03-25 | $3.48M 10-K · filed 2026-03-25 |
| 2025-09-30 | $2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.58M derived: sum of 2 quarters · filed 2025-11-06 | $1.52M 10-Q · filed 2025-11-06 | $3.36M derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-06-30 | $106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$957.00K 10-Q · filed 2025-08-12 | $886.00K derived: sum of 3 quarters · filed 2026-03-25 | -$818.00K derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-03-31 | -$1.06M 10-Q · filed 2025-05-14 | $780.00K derived: sum of 2 quarters · filed 2026-03-25 | -$924.00K derived: sum of 3 quarters · filed 2026-03-25 | $2.88M derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $139.00K derived: sum of 2 quarters · filed 2026-03-25 | $3.94M derived: sum of 3 quarters · filed 2026-03-25 | $3.81M 10-K · filed 2026-03-25 |
| 2024-09-30 | -$1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.10M derived: sum of 2 quarters · filed 2025-11-06 | $1.96M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $3.67M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$131.00K 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |